The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial.

Authors

Yireh Han, Hee Jeong Kim, Soo Yeon Baek, Sei-Hyun Ahn, Jai Min Ryu, Seung Il Kim, Eun-Gyeong Lee, Seock-Ah Im, Yongsik Jung, Min Ho Park, Kyong Hwa Park, Su Hwan Kang, Joon Jeong, Eunhwa Park, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Woosung Lim, Woo Chul Noh, Seonok Kim, Hyun-Ah Kim

Published in

Breast (Edinburgh, Scotland). Volume 89. Pages 104900. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

The Clinical Treatment Score post-5 years (CTS5), a prognostic tool for late distant recurrence, was validated in postmenopausal patients, but its value in premenopausal women remains unclear. Using 8-year ASTRRA data, we evaluated the prognostic performance of CTS5 in premenopausal breast cancer patients.
Patients without any event within the first 5 years were included in this analysis and were categorized into three risk groups based on CTS5 cutoff values. Late distant metastasis-free survival (DMFS) and overall survival were analyzed. Subgroup analyses were conducted to compare outcomes between the tamoxifen (TAM)-only and TAM + ovarian function suppression (OFS) groups.
Of the 1028 included premenopausal patients, late distant metastasis rates were 3.43% (low-risk, n = 466), 2.56% (intermediate-risk, n = 312), and 9.63% (high-risk, n = 270). The high-risk group showed a significantly higher risk of late DMFS compared to the low-risk group (HR = 3.32; 95% CI: 1.73-6.37; p < 0.001). The intermediate-risk group showed no significant difference (HR = 1.06; p = 0.876). When combining the low/intermediate-risk groups, the high-risk group maintained a significantly elevated risk (HR = 3.16; p = 0.015). OS results were consistent. Subgroup analysis confirmed that CTS5's prognostic ability was maintained in both the TAM-only (HR = 3.23; 0 = 0.004) and TAM + OFS groups (HR = 3.49; p = 0.029), consistently identifying high-risk patients.
In this randomized trial, unmodified CTS5 identifies high-risk patients but exhibits threshold inversions, making it unreliable for premenopausal extended therapy.

PMID:
42628334
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.